$Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1) a global, open-label, randomised, phase 3 trial /$
QR kód

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1) a global, open-label, randomised, phase 3 trial /

An unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R2) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus...

Teljes leírás

Elmentve itt :

Bibliográfiai részletek
Szerzők:	Falchi Lorenzo Nijland Marcel Huang Huiqiang Linton Kim M Seymour John F Tao Rong Kwiatek Michal Costa Abel Vassilakopoulos Theodoros P Greil Richard Jiménez-Ubieto Ana Gangatharan Shane A Benjamini Ohad Thieblemont Catherine Tucci Alessandra Elinder-Camburn Anna Illes Arpad Novak Jan Pavlovsky Miguel A McDonald Andrew Yoon Dok Hyun Maruyama Dai Sunkersett Gauri Mei Jian P Mukherjee Nabanita Zhu Feng Alshreef Abualbishr Favaro Elena Morschhauser Franck Kollaborációs szervezet: EPCORE FL-1 Investigators Modok Szabolcs Mikala Gábor Masszi András Rajnics Péter et al
Dokumentumtípus:	Cikk
Megjelent:	2026
Sorozat:	LANCET 407 No. 10524
Tárgyszavak:	Klinikai orvostan
doi:	10.1016/S0140-6736(25)02360-8
mtmt:	36495867
Online Access:	http://publicatio.bibl.u-szeged.hu/38758

Hasonló tételek

Off-label use of rituximab for systemic lupus erythematosus in Europe
Szerző: Ryden-Aulin Monica, et al.
Megjelent: (2016)

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Szerző: Wang Michael, et al.
Megjelent: (2025)

Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients Results of Real-Life Data From 11 Hungarian Centers /
Szerző: Varga Gergely, et al.
Megjelent: (2021)

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)
Szerző: Schneider Tamás, et al.
Megjelent: (2018)

Successful treatment of a primary uterine B-cell lymphoma with rituximab-CHOP immunochemotherapy
Szerző: Egyed Miklós, et al.
Megjelent: (2007)

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma final overall survival results of a randomised, open-label, phase 3 study /
Szerző: Robak Tadeusz, et al.
Megjelent: (2018)

Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP of an intravascular B-cell polychemotherapy
Szerző: Takács István, et al.
Megjelent: (2004)

Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life
Szerző: Szász Róbert, et al.
Megjelent: (2019)